Aardvark Therapeutics

The company is a clinical-stage biopharmaceutical firm focused on developing novel, small-molecule therapeutics designed to activate innate homeostatic pathways for the treatment of metabolic diseases, including obesity. Incorporated in Delaware, the company targets biological pathways associated with alleviating hunger, which it believes have the potential to deliver transformative outcomes for patients. Its research efforts are centered on developing selective compounds that target Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions.

The company’s initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to nutrients in food and play a role in the gut-brain axis. Research has demonstrated that activating these receptors can induce the secretion of endogenous signaling molecules, including cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1).

The company’s wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral, gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen. A Phase 3 clinical trial has been initiated for ARD-101 to address hyperphagia associated with Prader-Willi Syndrome (PWS). Additionally, the company plans to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity (HO) resulting from the treatment of craniopharyngioma, including surgery or radiation.

In a completed Phase 2 clinical trial involving subjects with hyperphagia associated with PWS, ARD-101 was well-tolerated and demonstrated clinical activity through a reduction in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. The company has aligned with the U.S. Food and Drug Administration (FDA) on a protocol for a potentially pivotal Phase 3 clinical trial, which was initiated in December 2024. Topline data is expected to be available in early 2026.